Corteva, Inc.

What they do

Corteva operates two segments, Seed and Crop Protection, selling products to farmers. Its portfolio includes genetically modified seeds, traits, and chemistries for weed, insect, and disease control. The company derives about 60% of sales in the first half of the year from the Northern Hemisphere planting season, and 40% in the second half from the Southern Hemisphere seed season.

Revenue drivers

• Seed segment — Sells corn, soybean, sunflower, and other seeds with traits; typically the largest revenue contributor, with seasonality peaking in the first half in the North and second half in the South.
• Crop Protection segment — Provides herbicides, insecticides, and fungicides; sales follow the same seasonal pattern and are boosted by partnerships and new product launches.
• Geographic sales mix — North America, Latin America, EMEA, and Asia-Pacific contribute 47%, 21%, 20%, and 12% of employees, respectively; sales are heavily weighted to the North American and Latin American growing seasons.

Recent performance

In Q2 2026, net sales fell 1% year-over-year to $6.38 billion (from $6.46 billion), and net income attributable to Corteva dropped to $1.16 billion from $1.31 billion. For the first half of 2026, net sales rose to $11.28 billion from $10.87 billion, but net income declined to $1.88 billion from $1.97 billion. Diluted EPS from continuing operations was $1.81 for Q2 2026, down from $2.02 in Q2 2025. Cash and marketable securities fell to $2.37 billion at June 30, 2026, from $4.53 billion at year-end 2025, while total debt rose to $4.875 billion.

Strategy

Corteva is investing in research and development (R&D spending of $388 million in Q2 2026) and expanding its product pipeline. The company has entered into partnerships, including a Bayer resolution payment and an FMC rimisoxafen prepayment, to access new chemistries and technologies. It is also focusing on operational efficiency, restructuring, and separation costs (e.g., $49 million restructuring charges and $79 million separation costs in Q2 2026). Management emphasizes maintaining a strong balance sheet and access to credit facilities for working capital and growth initiatives.

Risks

• Cybersecurity and data breaches — Corteva is a target of industrial espionage and cyberattacks, which could result in loss of trade secrets, business disruptions, or regulatory penalties.
• Weather and seasonality — Unfavorable weather can delay planting, affect quarterly results and sales mix, and severely impact overall sales, particularly in direct distribution channels.
• Environmental and litigation contingencies — The company faces ongoing environmental remediation costs and litigation, including PFAS-related liabilities that require cash outflows from discontinued operations.
• Debt and liquidity strain — Higher short-term debt to fund working capital and strategic payments (e.g., Bayer resolution, FMC prepayment) increases interest expense and refinancing risk.

Outlook

Corteva expects to generate adequate cash flows from operations and maintain access to capital markets to fund seasonal working capital, capital spending, dividends, and share repurchases. The company will continue to seek opportunities for growth through partnerships and innovation, while managing legacy liabilities. Management projects stable credit ratings and compliance with debt covenants, with $6.1 billion of committed/uncommitted credit lines available at June 30, 2026.